| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | CH5424802 | GDSC1000 | pan-cancer | AAC | -0.23 | 5e-09 |
| mRNA | A-770041 | GDSC1000 | pan-cancer | AAC | 0.33 | 5e-08 |
| mRNA | BRD-K03536150 | CTRPv2 | pan-cancer | AAC | 0.21 | 2e-07 |
| mRNA | CAL-101 | CTRPv2 | pan-cancer | AAC | 0.2 | 3e-07 |
| mRNA | YM-155 | CTRPv2 | pan-cancer | AAC | 0.21 | 6e-07 |
| mRNA | ABT-199 | CTRPv2 | pan-cancer | AAC | 0.23 | 2e-06 |
| mRNA | SRT-1720 | CTRPv2 | pan-cancer | AAC | 0.19 | 2e-06 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.16 | 9e-06 |
| mRNA | NVP-BEZ235 | CTRPv2 | pan-cancer | AAC | 0.2 | 2e-05 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |